GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » EBITDA Margin %

Elicera Therapeutics AB (OSTO:ELIC) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Elicera Therapeutics AB's EBITDA for the three months ended in Mar. 2024 was kr-5.34 Mil. Elicera Therapeutics AB's Revenue for the three months ended in Mar. 2024 was kr0.00 Mil. Therefore, Elicera Therapeutics AB's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Elicera Therapeutics AB EBITDA Margin % Historical Data

The historical data trend for Elicera Therapeutics AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB EBITDA Margin % Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - -1,310,800.00 - -

Elicera Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Elicera Therapeutics AB's EBITDA Margin %

For the Biotechnology subindustry, Elicera Therapeutics AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elicera Therapeutics AB's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's EBITDA Margin % falls into.



Elicera Therapeutics AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Elicera Therapeutics AB's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-16.31/0
= %

Elicera Therapeutics AB's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-5.335/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicera Therapeutics AB  (OSTO:ELIC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Elicera Therapeutics AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elicera Therapeutics AB (OSTO:ELIC) Business Description

Traded in Other Exchanges
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB (OSTO:ELIC) Headlines

No Headlines